EAU–ESMO consensus statements on the management of advanced and variant bladder cancer—an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees


Por: Horwich A., Babjuk M., Bellmunt J., Bruins H.M., De Reijke T.M., De Santis M., Gillessen S., James N., Maclennan S., Palou J., Powles T., Ribal M.J., Shariat S.F., Van Der Kwast T., Xylinas E., Agarwal N., Arends T., Bamias A., Birtle A., Black P.C., Bochner B.H., Bolla M., Boormans J.L., Bossi A., Briganti A., Brummelhuis I., Burger M., Castellano D., Cathomas R., Chiti A., Choudhury A., Compérat E., Crabb S., Culine S., De Bari B., DeBlok W., De Visschere P.J.L., Decaestecker K., Dimitropoulos K., Dominguez-Escrig J.L., Fanti S., Fonteyne V., Frydenberg M., Futterer J.J., Gakis G., Geavlete B., Gontero P., Grubmüller B., Hafeez S., Hansel D.E., Hartmann A., Hayne D., Henry A.M., Hernandez V., Herr H., Herrmann K., Hoskin P., Huguet J., Jereczek-Fossa B.A., Jones R., Kamat A.M., Khoo V., Kiltie A.E., Krege S., Ladoire S., Lara P.C., Leliveld A., Linares-Espinós E., Løgager V., Lorch A., Loriot Y., Meijer R., Carmen Mir M., Moschini M., Mostafid H., Müller A.-C., Müller C.R., N'Dow J., Necchi A., Neuzillet Y., Oddens J.R., Oldenburg J., Osanto S., Oyen W.J.G., Pacheco-Figueiredo L., Pappot H., Patel M.I., Pieters B.R., Plass K., Remzi M., Retz M., Richenberg J., Rink M., Roghmann F., Rosenberg J.E., Rouprêt M., Rouvière O., Salembier C., Salminen A., Sargos P., Sengupta S., Sherif A., Smeenk R.J., Smits A., Stenzl A., Thalmann G.N., Tombal B., Turkbey B., Vahr Lauridsen S., Valdagni R., Van Der Heijden A.G., Van Poppel H., Vartolomei M.D., Veskimäe E., Vilaseca A., Vives Rivera F.A., Wiegel T., Wiklund P., Williams A., Zigeuner R., Witjes J.A.

Publicada: 1 ene 2019
Resumen:
Background: Although guidelines exist for advanced and variant bladder cancer management, evidence is limited/conflicting in some areas and the optimal approach remains controversial. Objective: To bring together a large multidisciplinary group of experts to develop consensus statements on controversial topics in bladder cancer management. Design: A steering committee compiled proposed statements regarding advanced and variant bladder cancer management which were assessed by 113 experts in a Delphi survey. Statements not reaching consensus were reviewed; those prioritised were revised by a panel of 45 experts before voting during a consensus conference. Setting: Online Delphi survey and consensus conference. Participants: The European Association of Urology (EAU), the European Society for Medical Oncology (ESMO), experts in bladder cancer management. Outcome measurements and statistical analysis: Statements were ranked by experts according to their level of agreement: 1–3 (disagree), 4–6 (equivocal), 7–9 (agree). A priori (level 1) consensus was defined as =70% agreement and =15% disagreement, or vice versa. In the Delphi survey, a second analysis was restricted to stakeholder group(s) considered to have adequate expertise relating to each statement (to achieve level 2 consensus). Results and limitations: Overall, 116 statements were included in the Delphi survey. Of these, 33 (28%) statements achieved level 1 consensus and 49 (42%) statements achieved level 1 or 2 consensus. At the consensus conference, 22 of 27 (81%) statements achieved consensus. These consensus statements provide further guidance across a broad range of topics, including the management of variant histologies, the role/limitations of prognostic biomarkers in clinical decision making, bladder preservation strategies, modern radiotherapy techniques, the management of oligometastatic disease and the evolving role of checkpoint inhibitor therapy in metastatic disease. Conclusions: These consensus statements provide further guidance on controversial topics in advanced and variant bladder cancer management until a time where further evidence is available to guide our approach. © 2019 European Society for Medical Oncology

Filiaciones:
Horwich A.:
 Emeritus Professor, The Institute of Cancer Research, London, United Kingdom

Babjuk M.:
 Depatment of Urology, 2nd Faculty of Medicine, Hospital Motol, Charles University, Prague, Czech Republic

 Department of Urology, Medical University of Vienna, Vienna, Austria

Bellmunt J.:
 IMIM-Hospital del Mar Medical Research Institute, Barcelona, Spain

 Harvard Medical School, Boston, United States

Bruins H.M.:
 Department of Urology, Radboud University Medical Center, Nijmegen, Netherlands

De Reijke T.M.:
 Department of Urology, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, Netherlands

De Santis M.:
 Department of Urology, Medical University of Vienna, Vienna, Austria

 Department of Urology, Charité University Hospital, Berlin, Germany

Gillessen S.:
 Division of Cancer Sciences, University of Manchester, Manchester, United Kingdom

 The Christie NHS Foundation Trust, Manchester, United Kingdom

 Division of Oncology and Haematology, Kantonsspital St Gallen, St Gallen

 University of Bern, Bern, Switzerland

James N.:
 University Hospitals Birmingham NHS Foundation Trust, Birmingham

 Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, United Kingdom

Maclennan S.:
 Academic Urology Unit, University of Aberdeen, Aberdeen, United Kingdom

Palou J.:
 Department of Urology, Fundació Puigvert, Universitat Autònoma de Barcelona, Barcelona, Spain

Powles T.:
 The Royal Free NHS Trust, London

 Barts Cancer Institute, Queen Mary University of London, London, United Kingdom

Ribal M.J.:
 Uro-Oncology Unit, Hospital Clinic, University of Barcelona, Barcelona, Spain

Shariat S.F.:
 Depatment of Urology, 2nd Faculty of Medicine, Hospital Motol, Charles University, Prague, Czech Republic

 Department of Urology, Medical University of Vienna, Vienna, Austria

 Department of Urology, Weill Cornell Medical College, New York, United States

 Department of Urology, University of Texas Southwestern Medical Center, Dallas, United States

 Institute for Urology and Reproductive Health, I.M. Sechenov First Moscow State Medical University, Moscow, Russia, Russian Federation

 Weill Cornell Medical College, New York, United States

Van Der Kwast T.:
 Department of Pathology, Erasmus Medical Center, Rotterdam, Netherlands

Xylinas E.:
 Department of Urology, Bichat-Claude Bernard Hospital, Assistance Publique Hôpitaux de Paris, Paris

 Paris Descartes University, Paris, France

Agarwal N.:
 Huntsman Cancer Institute, University of Utah (NCI-CCC), Salt Lake City, United States

Arends T.:
 Urology Department, Canisius-Wilhelmina Ziekenhuis Nijmegen, Nijmegen, Netherlands

Bamias A.:
 2nd Propaedeutic Dept of Internal Medicine, Medical School, National & Kapodistrian University of Athens, Athens, Greece

Birtle A.:
 Division of Cancer Sciences, University of Manchester, Manchester, United Kingdom

 Rosemere Cancer Centre, Lancashire Teaching Hospitals, Preston, United Kingdom

Black P.C.:
 Department of Urologic Sciences, Vancouver Prostate Centre, University of British Columbia, Vancouver, Canada

Bochner B.H.:
 Department of Urology, Weill Cornell Medical College, New York, United States

 Urology Service, Department of Urology, Memorial Sloan Kettering Cancer Center, New York, United States

 Weill Cornell Medical College, New York, United States

Bolla M.:
 Emeritus Professor of Radiation Oncology, Grenoble - Alpes University, Grenoble, France

Boormans J.L.:
 Department of Urology, Erasmus University Medical Center, Rotterdam, Netherlands

Bossi A.:
 Department of Radiation Oncology, Gustave Roussy Institute, Villejuif, France

Briganti A.:
 Department of Urology, Urological Research Institute, Milan

 Vita-Salute University, San Raffaele Scientific Institute, Milan, Italy

Brummelhuis I.:
 Department of Urology, Radboud University Medical Center, Nijmegen, Netherlands

Burger M.:
 Department of Urology, Caritas-St. Josef Medical Center, University of Regensburg, Regensburg, Germany

Castellano D.:
 Medical Oncology Department, 12 de Octubre University Hospital (CIBERONC), Madrid, Spain

Cathomas R.:
 Department Innere Medizin, Abteilung Onkologie und Hämatologie, Kantonsspital Graubünden, Chur, Switzerland

Chiti A.:
 Department of Biomedical Sciences, Humanitas University, Milan

 Humanitas Research Hospital, Milan, Italy

Choudhury A.:
 Division of Cancer Sciences, University of Manchester, Manchester, United Kingdom

 The Christie NHS Foundation Trust, Manchester, United Kingdom

Compérat E.:
 Department of Pathology, Tenon Hospital, HUEP, Paris

 Sorbonne University, Paris, France

Crabb S.:
 Cancer Sciences Unit, University of Southampton, Southampton, United Kingdom

Culine S.:
 Department of Cancer Medicine, Hôpital Saint Louis, Paris

De Bari B.:
 Radiation Oncology Department, centre Hospitalier Régional Universitaire “Jean Minjoz” of Besançon, INSERM UMR 1098, Besançon, France

 Radiation Oncology Department, centre Hospitalier Universitaire Vaudois, Université de Lausanne, Lausanne, Switzerland

DeBlok W.:
 Department of Urology, University Medical Center Utrecht, Utrecht, Netherlands

De Visschere P.J.L.:
 Department of Radiology and Nuclear Medicine, Division of Genitourinary Radiology and Mammography, Ghent University Hospital, Ghent

Decaestecker K.:
 Department of Urology, Ghent University Hospital, Ghent, Belgium

Dimitropoulos K.:
 Department of Urology, Aberdeen Royal Infirmary, Aberdeen, United Kingdom

Dominguez-Escrig J.L.:
 Servicio de Urología, Fundación Instituto Valenciano de Oncología, Valencia, Spain

Fanti S.:
 Department of Nuclear Medicine, Policlinico S Orsola, University of Bologna, Bologna, Italy

Fonteyne V.:
 Department of Radiotherapy Oncology, Ghent University Hospital, Ghent, Belgium

Frydenberg M.:
 Department of Surgery, Faculty of Medicine, Nursing and Health Sciences, Monash University, Clayton, Australia

Futterer J.J.:
 Department of Radiology and Nuclear Medicine, Radboud University Medical Center, Nijmegen, Netherlands

Gakis G.:
 Department of Urology and Paediatric Urology, University Hospital of Würzburg, Julius-Maximillians University, Würzburg, Germany

Geavlete B.:
 Department of Urology, Saint John Emergency Clinical Hospital, Bucharest, Romania

Gontero P.:
 Division of Urology, Molinette Hospital, University of Studies of Torino, Torino, Italy

Grubmüller B.:
 Department of Urology, Medical University of Vienna, Vienna, Austria

Hafeez S.:
 Division of Radiotherapy and Imaging, The Institute of Cancer Research, London

 Department of Clinical Oncology, The Royal Marsden NHS Foundation Trust, London, United Kingdom

Hansel D.E.:
 Department of Urology, University of California, San Diego Pathology, La Jolla, United States

Hartmann A.:
 Institute of Pathology, Friedrich-Alexander University (FAU) Erlangen-Nürnberg, Erlangen, Germany

Hayne D.:
 Department of Urology, UWA Medical School, University of Western Australia, Perth, Australia

Henry A.M.:
 Leeds Institute of Medical Research, University of Leeds, Leeds, United Kingdom

Hernandez V.:
 Department of Urology, Hospital Universitario Fundación de Alcorcón, Madrid, Spain

Herr H.:
 Urology Service, Department of Urology, Memorial Sloan Kettering Cancer Center, New York, United States

Herrmann K.:
 Department of Nuclear Medicine, Universitätsklinikum Essen, Essen, Germany

Hoskin P.:
 Division of Cancer Sciences, University of Manchester, Manchester, United Kingdom

 The Christie NHS Foundation Trust, Manchester, United Kingdom

 Mount Vernon Centre for Cancer Treatment, London, United Kingdom

Huguet J.:
 Department of Urology, Fundació Puigvert, Universitat Autònoma de Barcelona, Barcelona, Spain

Jereczek-Fossa B.A.:
 Department of Oncology and Hemato-oncology, University of Milan, Milan

 Division of Radiotherapy, IEO European Institute of Oncology, IRCCS, Milan, Italy

Jones R.:
 Institute of Cancer Sciences, College of Medicine, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom

Kamat A.M.:
 Department of Urology – Division of Surgery, The University of Texas, MD Anderson Cancer Center, Houston, United States

Khoo V.:
 Division of Radiotherapy and Imaging, The Institute of Cancer Research, London

 Department of Clinical Oncology, The Royal Marsden NHS Foundation Trust, London, United Kingdom

 Department of Medicine, University of Melbourne, Melbourne

 Monash University, Melbourne, Australia

Kiltie A.E.:
 CRUK/MRC Oxford Institute for Radiation Oncology, University of Oxford, Oxford, United Kingdom

Krege S.:
 Department of Urology, Pediatric Urology and Urologic Oncology, Kliniken Essen-Mitte, Essen, Germany

Ladoire S.:
 Department of Medical Oncology, Centre Georges François Leclerc, Dijon, France

Lara P.C.:
 Department of Oncology, Hospital Universitario San Roque, Canarias

 Universidad Fernando Pessoa, Canarias, Spain

Leliveld A.:
 Department of Urology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands

Linares-Espinós E.:
 Department of Urology, University Hospital La Paz, Madrid, Spain

Løgager V.:
 Department of Radiology, Copenhagen University Hospital Herlev and Gentofte, Herlev, Denmark

Lorch A.:
 Department of Medical Oncology and Hematology, University Hospital Zürich, Zürich, Switzerland

Loriot Y.:
 Département de Médecine Oncologique, Gustave Roussy, INSERM U981, université Paris-Sud, Université Paris-Saclay, Villejuif, France

Meijer R.:
 UMC Utrecht Cancer Center, MS Oncologic Urology, Utrecht, Netherlands

Carmen Mir M.:
 Servicio de Urología, Fundación Instituto Valenciano de Oncología, Valencia, Spain

Moschini M.:
 Department of Urology, Luzerner Kantonsspital, Luzern, Switzerland

Mostafid H.:
 Department of Urology, Royal Surrey County Hospital, Guildford, United Kingdom

Müller A.-C.:
 Department of Radiation Oncology, Eberhard Karls University, Tübingen, Germany

Müller C.R.:
 Cancer Treatment Centre, Sorlandet Hospital, Kristiansand, Norway

N'Dow J.:
 Academic Urology Unit, University of Aberdeen, Aberdeen, United Kingdom

 Department of Urology, Aberdeen Royal Infirmary, Aberdeen, United Kingdom

Necchi A.:
 Department of Medical Oncology, Istituto Nazionale Tumori of Milan, Milan, Italy

Neuzillet Y.:
 Department of Urology, Hospital Foch, University of Versailles-Saint-Quentin-en-Yvelines, Suresnes, France

Oddens J.R.:
 Department of Urology, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, Netherlands

Oldenburg J.:
 Department of Oncology, Akershus University Hospital, Lørenskog

 Faculty of Medicine, University of Oslo, Oslo, Norway

Osanto S.:
 Department of Clinical Oncology, Leiden University Medical Center, Leiden

Oyen W.J.G.:
 Department of Biomedical Sciences, Humanitas University, Milan

 Humanitas Research Hospital, Milan, Italy

 Department of Radiology and Nuclear Medicine, Radboud University Medical Center, Nijmegen, Netherlands

 Department of Radiology and Nuclear Medicine, Rijnstate Hospital, Arnhem, Netherlands

Pacheco-Figueiredo L.:
 Department of Urology, Centro Hospitalar São João, Porto

 Life and Health Sciences Research Institute (ICVS), School of Medicine, University of Minho, Braga, Portugal

Pappot H.:
 Department of Oncology, Rigshospitalet, University Hospital of Copenhagen, Copenhagen, Denmark

Patel M.I.:
 Department of Urology, Westmead Hospital, University of Sydney, Sydney, Australia

Pieters B.R.:
 Department of Radiation Oncology, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam

Plass K.:
 EAU Guidelines Office, Arnhem, Netherlands

Remzi M.:
 Department of Urology, Medical University of Vienna, Vienna, Austria

Retz M.:
 Department of Urology, Rechts der Isar Medical Center, Technical University of Munich, Munich, Germany

Richenberg J.:
 Department of Imaging and Nuclear Medicine, Royal Sussex County Hospital, Brighton

 Brighton and Sussex Medical School, Brighton, United Kingdom

Rink M.:
 Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg

Roghmann F.:
 Department of Urology, Ruhr-University Bochum, Marien Hospital, Herne, Germany

Rosenberg J.E.:
 Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, United States

 Weill Cornell Medical College, New York, United States

Rouprêt M.:
 Department of Urology, Sorbonne Université, GRC n°5, ONCOTYPE-URO, AP-HP, Hôpital Pitié-Salpêtrière, Paris

Rouvière O.:
 Hospices Civils de Lyon, Service d'Imagerie Urinaire et Vasculaire, Hôpital Edouard Herriot, Lyon

 Université de Lyon, université Lyon 1, faculté de Médecine Lyon Est, Lyon, France

Salembier C.:
 Department of Radiation Oncology, Europe Hospitals Brussels, Brussels, Belgium

Salminen A.:
 Department of Urology, University Hospital of Turku, Turku, Finland

Sargos P.:
 Department of Radiotherapy, Institut Bergonié, Bordeaux, France

Sengupta S.:
 Monash University, Melbourne, Australia

 Department of Surgery, Austin Health, University of Melbourne, Melbourne

 Eastern Health Clinical School, Monash University, Melbourne, Australia

Sherif A.:
 Department of Surgical and Perioperative Sciences, Urology and Andrology, Umeå University, Umeå, Sweden

Smeenk R.J.:
 Department of Radiation Oncology, Radboud University Medical Center, Nijmegen, Netherlands

Smits A.:
 Department of Urology, Radboud University Medical Center, Nijmegen, Netherlands

Stenzl A.:
 Department of Urology, Eberhard Karls University Tübingen, Tübingen, Germany

Thalmann G.N.:
 Department of Urology, Inselspital, Bern University Hospital, Berne, Switzerland

Tombal B.:
 Division of Urology, IREC, Cliniques Universitaires Saint Luc, UCL, Brussels, Belgium

Turkbey B.:
 Molecular Imaging Program, National Cancer Institute, Bethesda, United States

Vahr Lauridsen S.:
 Department of Urology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark

Valdagni R.:
 Department of Oncology and Hemato-oncology, Università degli Studi di Milano, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

Van Der Heijden A.G.:
 Department of Urology, Radboud University Medical Center, Nijmegen, Netherlands

Van Poppel H.:
 Department of Urology, University Hospitals Leuven, Leuven, Belgium

Vartolomei M.D.:
 Department of Urology, Medical University of Vienna, Vienna, Austria

 Department of Cell and Molecular Biology, George Emil Palade University of Medicine, Pharmacy, Science, and Technology of Targu Mures, Targu Mures, Romania

Veskimäe E.:
 Department of Urology, Tampere University Hospital, Tampere, Finland

Vilaseca A.:
 Uro-Oncology Unit, Hospital Clinic, University of Barcelona, Barcelona, Spain

Vives Rivera F.A.:
 Clinica HematoOncologica Bonadona Prevenir, Universidad Metropolitana, Clinica Club de Leones, Barranquilla, Colombia

Wiegel T.:
 Department of Radiation Oncology, University Hospital Ulm, Ulm, Germany

Wiklund P.:
 Icahn School of Medicine, Mount Sinai Health System, New York City, United States

 Department of Urology, Karolinska Institutet, Stockholm, Sweden

Williams A.:
 Department of Urology, Auckland City Hospital, Auckland, New Zealand

Zigeuner R.:
 Department of Urology, Medizinische Universität Graz, Graz, Austria

Witjes J.A.:
 Department of Urology, Radboud University Medical Center, Nijmegen, Netherlands
ISSN: 09237534
Editorial
ELSEVIER, RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS, Reino Unido
Tipo de documento: Article
Volumen: 30 Número: 11
Páginas: 1697-1727
WOS Id: 000507594800008
ID de PubMed: 31740927
imagen All Open Access, Bronze

MÉTRICAS